Meta-Analysis Links Rosiglitazone (Avandia) to Risk of Myocardial Infarction - CME Teaching Brief® - MedPage Today

Meta-Analysis Links Rosiglitazone (Avandia) to Risk of Myocardial Infarction - CME Teaching Brief® - MedPage Today: "CLEVELAND, May 21 -- A meta-analysis of data from 42 clinical trials found a 43% increase in relative risk of myocardial infarction among type 2 diabetics treated with rosiglitazone (Avandia).

The odds ratio for MI was 1.43 (95% confidence interval 1.03-1.98, P=0.03), said Steven E. Nissen, M.D., of the Cleveland Clinic, lead author of the meta-analysis, which was released online today by the New England Journal of Medicine."